Peer-reviewed veterinary case report
Ambrisentan helped 5 dogs with worsening pulmonary hypertension
By Goya, Seijirow et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2022·Department of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Adjunct ambrisentan therapy had clinical benefits in 5 dogs with sildenafil-refractory pulmonary hypertension.
- Species:
- dog
Plain-English summary
Five dogs with severe pulmonary hypertension were not responding well to sildenafil, a common medication for this condition. Their owners noticed worsening symptoms like decreased appetite and activity. When the veterinarians added ambrisentan to their treatment, the dogs showed improvements in their appetite, activity levels, and breathing. Although some heart measurements didn't change significantly, the dogs felt better overall without any noticeable side effects. This suggests that ambrisentan can be a helpful addition for dogs struggling with pulmonary hypertension that isn't improving with sildenafil alone.
People also search for: dog pulmonary hypertension treatment · sildenafil side effects in dogs · ambrisentan for dogs with heart problems
Abstract
Although sildenafil is used in dogs with severe pulmonary hypertension, they sometimes become resistant and clinical signs deteriorate over time. The objective of this study was to determine the benefits of adjunct ambrisentan therapy in dogs with sildenafil-refractory pulmonary hypertension. In 5 dogs with severe pulmonary hypertension with deteriorating clinical signs despite ongoing sildenafil treatment, adding ambrisentan improved appetite, activity, and respiratory functions. Although peak tricuspid valve regurgitation velocity, as measured by Doppler echocardiography, did not necessarily decrease after ambrisentan administration, there was improved partial pressure of arterial oxygen and the alveolar-arterial oxygen gradient, with no apparent side effects. We concluded that ambrisentan has potential as an adjunct treatment in dogs with pulmonary hypertension that are refractory to sildenafil therapy. Key clinical message: Ambrisentan improved clinical signs in dogs with sildenafil-refractory pulmonary hypertension.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35502246/